6-Fluoronicotinic acid

We are 6-Fluoronicotinic acid CAS:403-45-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:6-Fluoronicotinic acid
CAS.NO:403-45-2
Synonyms:6-Fluoronicotinic acid
6-fluoropyridine-3-carboxylic acid
2-Fluoro-5-pyridinecarboxylic Acid
 
Physical and Chemical Properties:
Density 1.4±0.1 g/cm3
Boiling Point 309.4±22.0 °C at 760 mmHg
Melting Point 144-148 °C(lit.)
Molecular Formula C6H4FNO2
Molecular Weight 141.100
Flash Point 140.9±22.3 °C
 
Specification:
Appearance:White to off-white solid
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate

6-Fluoronicotinic acid


Related News: As proof-of-principle for the unique advantages arising from selecting a single engineered iPSC clone for the production of CAR T-cell therapy, the scientists assessed 747 clones after engineering a pool of cells using CRISPR. It was found that only about 2% of clones met the Company’s standards for overall quality including containing both bi-allelic disruption of the TCR, proper insertion of the CAR into the TRAC locus without random transgene integrations, and no evidence of off-target genomic modifications or translocations.L-Histidine Monohydrochloride Monohydrate CAS:5934-29-2 On the basis of achieving low-cost and high-quality processes, production capacity will become the core driving force for API companies to break through sales bottlenecks.,3,4,6-Tetra-O-benzyl-D-gluconic acid-δ-lactone CAS:13096-62-3 The purpose of APIs according to the FDA is to cause ‘pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body.3,4-Difluorobenzoic acid Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.

Related Products
Product Name
(NZ)-N-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]hydroxylamine View Details
7-chloroheptan-1-ol View Details
2-[(2-methylphenoxy)methyl]benzoyl cyanide View Details
N-Boc-L-glutamic Acid 5-Cyclohexyl Ester manufacturer 4-(4-bromophenyl)-N,N-diphenylaniline manufacturer methyl 6-chloro-4-hydroxy-1,1-dioxo-2H-thieno[2,3-e]thiazine-3-carboxylate manufacturer 3-Fluoro-2-methylphenol manufacturer Pyridoxine dipalmitate manufacturer